In NSCLC, various novel ADCs targeting oncogenic targets, including HER2, HER3, Trophoblast cell-surface antigen 2 (TROP2), MET, NECTIN4, Tissue Factor (TF), Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), mesothelin, and LIV1, are in clinical trials [3]. This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.